Compass Therapeutics (NASDAQ:CMPX) & Cardiff Oncology (NASDAQ:CRDF) Critical Review

Cardiff Oncology (NASDAQ:CRDF) and Compass Therapeutics (NASDAQ:CMPX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Profitability

This table compares Cardiff Oncology and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cardiff Oncology	-6,238.17%	-73.97%	-60.40%
Compass Therapeutics	N/A	-32.37%	-30.67%

Risk & Volatility

Cardiff Oncology has a beta of 1.77, suggesting that its share price is 77% more volatile than the S&P 500. Comparatively, Compass Therapeutics has a beta of 1.17, suggesting that its share price is 17% more volatile than the S&P 500.

Institutional & Insider Ownership

16.3% of Cardiff Oncology shares are owned by institutional investors. Comparatively, 68.4% of Compass Therapeutics shares are owned by institutional investors. 7.8% of Cardiff Oncology shares are owned by company insiders. Comparatively, 28.5% of Compass Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings for Cardiff Oncology and Compass Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cardiff Oncology	0	0	3	0	3.00
Compass Therapeutics	0	2	5	0	2.71

Cardiff Oncology presently has a consensus price target of $10.33, indicating a potential upside of 138.10%. Compass Therapeutics has a consensus price target of $11.17, indicating a potential upside of 197.78%. Given Compass Therapeutics’ higher probable upside, analysts plainly believe Compass Therapeutics is more favorable than Cardiff Oncology.

Earnings & Valuation

This table compares Cardiff Oncology and Compass Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cardiff Oncology	$490,000.00	452.87	-$41.44 million	($0.94)	-4.62
Compass Therapeutics	N/A	N/A	-$42.49 million	($0.37)	-10.13

Cardiff Oncology has higher revenue and earnings than Compass Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.

Summary

Compass Therapeutics beats Cardiff Oncology on 8 of the 13 factors compared between the two stocks.

About Cardiff Oncology

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.